Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements By Ogkologos - June 11, 2026 120 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FIGHT-302 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves New Initial Treatment Option for Some Metastatic Prostate Cancers August 4, 2023 Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will... March 15, 2019 Mom Walks In To Comfort Scared Son After Surgery And Sees... June 26, 2019 Three Brothers Under The Age Of 6 Are All Fighting The... February 7, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Inavolisib Mom’s Early-Stage Breast Cancer Discovered When She Undergoes Testing to Donate... How Can Hormone Replacement Therapy for Menopause Impact My Cancer Risk? American Cancer Society Report Shows Economic, Racial Disparities in Cancer Outcomes
